US EditionPublished • loading... • Updated
Ionis Pharmaceuticals, Inc. (IONS): Analyst Consensus Highlights 34.76% Upside Potential
Summary by DirectorsTalk Interviews
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Ionis Pharmaceuticals, Inc. (IONS): Analyst Consensus Highlights 34.76% Upside Potential
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) stands at a pivotal moment for investors seeking opportunities in the healthcare sector. As a biotechnology stalwart based in Carlsbad, California, Ionis focuses on RNA-targeted medicines, a niche that promises both intrigue and potential for high returns. With a market capitalization of $12.1 billion, Ionis occupies a significant position in the biotech industry. Currently trading at $73.27, Ionis has …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
